OmniAb, Inc. (NASDAQ: OABI) Q2 2025 Earnings | 08/07/2025

About this video

OmniAb, Inc. reported its Q2 2025 financial results, revealing significant revenue decline amid ongoing strategic initiatives and partner ecosystem growth. The company posted revenue of $3.9 million, down from $7.6 million in the same quarter last year, primarily due to lower milestone and service revenue as a small-molecule ion channel program was discontinued. Despite this, OmniAb maintained full-year 2025 guidance with expected revenue between $20 million and $25 million. Net loss increased to $15.9 million, or $0.15 per share, compared to $13.6 million, or $0.13 per share, in Q2 2024, while operating expenses were reduced to $20.1 million from $23.9 million, driven by lower stock-based compensation, fewer headcount, and decreased external program expenses. Cash usage totaled $2 million for the quarter, supported by milestone payments and proceeds from an asset sale. Operationally, OmniAb celebrated strong partner growth, reaching 100 active partners from 90 at year-end 2024, and expanded its active program count to 381, with a year-to-date net increase of 18 programs. Importantly, post-discovery and clinical-stage programs grew steadily, reflecting diversification into inflammation, fibrosis, renal, dermatology, oncology, and CNS therapeutic areas. A major highlight was the launch of the xPloration Partner Access Program, designed to enhance antibody discovery and screening capabilities for partners. The program received industry recognition and early sales traction, positioning it as a promising new revenue stream. Looking forward, management remains optimistic about multiple upcoming clinical program entries and continued partner expansion. Risks include near-term revenue pressure and the challenges of scaling new technologies and partnerships. About Inside Ticker: Inside Ticker delivers timely, in-depth financial news and earnings analysis to empower investors with actionable insights on global companies across sectors. For comprehensive video analysis and real-time updates, visit https://www.insideticker.com/. #OmniAb #OABI #Q22025 #Earnings #FinancialResults #Revenue #NetLoss #EPS #Growth #Biotech #AntibodyDiscovery #xPloration #PartnerGrowth #AntibodyScreening #ClinicalDevelopment #PharmaPartnerships #Biopharma #Innovation #Therapeutics #Immunology #Oncology #Inflammation #Fibrosis #RenalDisease #Dermatology #CNS #MilestoneRevenue #TechnologyLaunch #AssetSale #CostReduction #InvestorUpdates #InsideTicker #NASDAQ #BiotechNews #DrugDevelopment #LifeSciences #HealthcareInnovation #PipelineGrowth #BiotechPartnerships #ResearchAndDevelopment #LabAutomation